tiprankstipranks
Advertisement
Advertisement

NBIX Stock Latest News

Neurocrine reports new post-hoc data from KINECT 4 trial
The FlyNeurocrine reports new post-hoc data from KINECT 4 trial
3d ago
NBIX
Neurocrine presents new data showing Improvements with INGREZZA
PremiumThe Fly
Neurocrine presents new data showing Improvements with INGREZZA
4d ago
NBIX
Myles Minter Reiterates Buy on Neurocrine, Citing Diversified Commercial Franchise, Robust Ingrezza Growth, and Catalyst-Rich Late-Stage Pipeline
PremiumRatings
Myles Minter Reiterates Buy on Neurocrine, Citing Diversified Commercial Franchise, Robust Ingrezza Growth, and Catalyst-Rich Late-Stage Pipeline
9d ago
NBIX
Meta Platforms upgraded, Okta downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Meta Platforms upgraded, Okta downgraded: Wall Street’s top analyst calls
9d ago
KNX
SHW
Neurocrine reinstated with a Buy at Goldman Sachs
PremiumThe Fly
Neurocrine reinstated with a Buy at Goldman Sachs
10d ago
NBIX
Neurocrine price target raised to $183 from $180 at RBC Capital
PremiumThe FlyNeurocrine price target raised to $183 from $180 at RBC Capital
13d ago
NBIX
Neurocrine Shareholders Reelect Directors and Approve Governance Measures
Premium
Company Announcements
Neurocrine Shareholders Reelect Directors and Approve Governance Measures
14d ago
8K
NBIX
Neurocrine initiated with Outperform at Bernstein on long runway of key drugs
Premium
The Fly
Neurocrine initiated with Outperform at Bernstein on long runway of key drugs
21d ago
NBIX
Neurocrine initiated with an Outperform at Bernstein
PremiumThe Fly
Neurocrine initiated with an Outperform at Bernstein
21d ago
NBIX
Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors
PremiumCompany Announcements
Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors
23d ago
NBIX
Neurocrine announces new data from a clinician survey in Ingrezza
PremiumThe Fly
Neurocrine announces new data from a clinician survey in Ingrezza
24d ago
NBIX
Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio
PremiumCompany Announcements
Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio
24d ago
8K
NBIX
Neurocrine completes acquisition of Soleno Therapeutics
PremiumThe FlyNeurocrine completes acquisition of Soleno Therapeutics
24d ago
NBIX
SLNO
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
Premium
The Fly
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
27d ago
AARD
NBIX
Neurocrine price target raised to $185 from $177 at JPMorgan
Premium
The Fly
Neurocrine price target raised to $185 from $177 at JPMorgan
1M ago
NBIX
Neurocrine price target raised to $155 from $140 at Truist
PremiumThe Fly
Neurocrine price target raised to $155 from $140 at Truist
1M ago
NBIX
Neurocrine price target raised to $155 from $150 at Deutsche Bank
PremiumThe Fly
Neurocrine price target raised to $155 from $150 at Deutsche Bank
1M ago
NBIX
Neurocrine treatment of Friedreich ataxia granted orphan designation
PremiumThe Fly
Neurocrine treatment of Friedreich ataxia granted orphan designation
1M ago
NBIX
Neurocrine price target raised to $246 from $242 at Citi
PremiumThe Fly
Neurocrine price target raised to $246 from $242 at Citi
1M ago
NBIX
Neurocrine price target raised to $207 from $190 at Piper Sandler
PremiumThe FlyNeurocrine price target raised to $207 from $190 at Piper Sandler
1M ago
NBIX
SLNO
Neurocrine price target raised to $191 from $185 at Morgan Stanley
Premium
The Fly
Neurocrine price target raised to $191 from $185 at Morgan Stanley
1M ago
NBIX
Neurocrine price target raised to $230 from $220 at Oppenheimer
Premium
The Fly
Neurocrine price target raised to $230 from $220 at Oppenheimer
1M ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >